Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)

por Horneff, G, Minden, K, Foeldvari, I, Kuemmerle-Deschner, J, Thon, A, Girschick, H, Huppertz, HI
Publicado 2008

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab

por Horneff, G, Fitter, S, Huppertz, HI, Foeldvari, I, Kuemmerle-Deschner, K, Kuester, R, Tzaribacev, N, Thon, A, Borte, M, Ganser, G, Trauzeddel, R, Minden, K
Publicado 2011

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept

por Ruperto, N, Lovell, DJ, Li, T, Paz, E, Horneff, G, Huppertz, HI, Deslandre, CJ, Minden, K, Punaro, M, Nunez, AF, Sigal, L, Block, A, Covucci, A, Martini, A, Giannini, EH
Publicado 2008

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)

por De Benedetti, F, Brunner, HI, Baildam, E, Burgos-Vargas, R, Horneff, G, Huppertz, HI, Minden, K, Myones, BL, Onel, K, Wang, J, Bharucha, K, Lovell, D, Martini, A, Ruperto, N
Publicado 2013

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis

por Ruperto, N, Lovell, D, Goodman, S, Reiff, A, Nemcová, D, Quartier, P, Joos, R, Gerloni, V, Bohnsack, J, Wagner-Weiner, L, Huppertz, HI, Olson, N, Medich, J, McIlraith, M, Martini, A, Giannini, E
Publicado 2008